

CERTIFICATE OF ELECTRONIC FILING

This correspondence is being filed with the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, via electronic filing, on the date below:

March 23, 2007

Date



Sharon V. Hart

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Philip E. Thorpe and Sophia Ran (As Amended)

Serial No.: 10/621,269

Filed: July 15, 2003

For: Selected Antibody Compositions for Binding to Aminophospholipids (As Amended)

Group Art Unit: 1642

Examiner: Goddard, L.

Atty. Dkt. No.: 4001.003000

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that the present Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record in the present case. The required copies of the listed documents are enclosed, although copies of U.S. patent documents are no longer required under 37 C.F.R. § 1.98(a)(2)(ii).

In accordance with 37 C.F.R. §§ 1.97(g),(h), the present Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

First and second Official Actions reflecting examination on the merits have been received in the present application. However, the present Supplemental Information Disclosure Statement is being filed prior to the mailing of a final Official Action, notice of allowance or an action that otherwise closes prosecution, and is timely filed in accordance with 37 C.F.R. § 1.97(c)(2) without a fee in light of the following information.

In accordance with 37 C.F.R. § 1.97(e)(2), it is hereby certified that the documents listed on the accompanying Form PTO-1449 were not cited in a communication from a foreign patent office in a counterpart foreign application. The listed documents were cited in an Official Action on the merits in a co-pending application of the present inventors, Serial No. 10/642,064 (Attorney Docket No. 4001.003086), mailed from the P.T.O. on January 12, 2007, which is less than three months before the filing of the present statement, and the listed documents could not have been submitted before receipt.

No fees should be due in connection herewith. However, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Examiner should contact the undersigned representative to discuss deduction from Peregrine Pharmaceuticals, Inc. Deposit Account No. 50-3493/4001.003000.

Respectfully submitted,

PEREGRINE PHARMACEUTICALS, INC.
Customer No. 000052101



Shelley P.M. Fussey, Ph.D.
Reg. No. 39,458
Agent for Applicants

5353 W. Alabama, Suite 306
Houston, Texas, 77056
(713) 439 0108
Date: March 23, 2007